Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||New therapeutic approaches to subarachnoid hemorrhage|
|Citation:||Expert Opinion on Investigational Drugs, 2012; 21(6):845-859|
|Publisher:||Ashley Publications Ltd|
|Christine Barry, Renee J Turner, Frances Corrigan & Robert Vink|
|Abstract:||Introduction: Subarachnoid hemorrhage (SAH) is associated with significant morbidity and mortality, even for patients who receive early neurointerventionist management. Areas covered: Early mechanisms of secondary brain injury precede the delayed vasospasm phase and contribute to the poor outcome. These mechanisms and their intervention are discussed, including high intracranial pressure (ICP), low cerebral perfusion pressure (CPP), acute vasospasm, disturbed cerebral autoregulation, cerebral edema, oxidative stress, seizures, microvascular damage and hyperglycemia. Erythropoietin, statins and magnesium have been particularly promising in experimental studies. Expert opinion: Multiple mechanisms, including delayed vasospasm, may contribute to cerebral ischemia and poor outcome following SAH. Treatments that simultaneously target multiple secondary injury pathways show significant potential as therapeutic agents, particularly those that attenuate vasospasm in addition to having other neuroprotective properties.|
|Rights:||© 2012 Informa UK Ltd|
|Appears in Collections:||Aurora harvest|
Medical Sciences publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.